Repeated noninfectious endophthalmitis after intravitreal administration of bevacizumab: A report of two cases

Retinal Cases and Brief Reports

Volumn 4, Issue 3, 2010, Pages 220-223

  Soudry, Shiri ^a,b   Loewenstein, Anat ^a,b   Moisseiev, Joseph ^b,c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Age related macular degeneration; Intravitreal bevacizumab; Repeat injection; Sterile endophthalmitis

Indexed keywords

EID: 79955075743     PISSN: 19351089     EISSN: 19371578     Source Type: Journal    
DOI: 10.1097/ICB.0b013e3181a59d92     Document Type: Article

References (16)

1. Rosenfeld PJ, Moshfegi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36: 331-335. (Pubitemid 41073112)
2. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
3. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23:240-242. (Pubitemid 46986604)
4. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
5. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-567. (Pubitemid 351589565)
6. Nelson ML, Tenant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23: 686-691. (Pubitemid 37315056)
7. Taban M, Singh RP, Chung JY, et al. Sterile endophthalmitis after triamcinolone: a possible association with uveitis. Am J Ophthalmol 2007;144:50-54.
8. Yenerel NM, Dinc UA, Gorgun E. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection. J Ocul Pharmacol Ther 2008;24:362-363. (Pubitemid 351733229)
9. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:779-781.
10. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-516. (Pubitemid 40489924)
11. Rosenfeld PJ, Schwartz SD, Blumenkrantz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112: 1048-1053. (Pubitemid 40797460)
12. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19: 361-372. (Pubitemid 44279358)
13. Grisanti S, Tatar O, Gelisken F, et al. Histopathologic evaluation of choroidal neovascular membranes following intravitreal bevacizumab injection. Paper presented at: Combined Meeting of Club Jules Gonin and The Retina Society; Cape Town, South Africa. October 15-20, 2006.
14. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-345. (Pubitemid 40767935)
15. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-881. (Pubitemid 44547439)
16. Ziemssen F, Warga M, Neuhann IM, et al. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? Br J Ophthalmol 2006;90:922. (Pubitemid 43974012)